IT202000017188A1 - DERMATOLOGICAL COMPOSITION FOR REBALANCING THE SKIN, TO INCREASE IRMHYDRATION AND ELASTICITY AND TO REDUCE DISCOLORATION - Google Patents

Description

Description of the Industrial Invention entitled:

?DERMATOLOGICAL COMPOSITION FOR REBALANCING THE SKIN, TO INCREASE ITS HYDRATION AND ELASTICITY? AND TO REDUCE DISCOLORATIONS?

Description

field of technique

Object of the present invention ? a dermatological composition that allows you to rebalance the skin, to increase the degree of hydration of the skin, the degree of elasticity? and to simultaneously reduce skin discolouration. Therefore the present invention belongs to the field of dermatology and cosmetics.

State of the art

In the cosmetics sector, and in particular in that of classic foundations, the first products to be placed on the market were BB creams and CC creams, all-in-one foundations with finality? basic moisturizers and dyes.

From our market analysis we have not identified any brand or product that has gone so far as to talk about the fusion of skincare and make-up and in particular, analyzing more? in depth the foundation market that represents the (make) UP part of a possible FUSION product, and identifying different areas of investigation, isn't it? highlighted the presence of a product that combines the effects of rebalancing, hydration, elasticity? skin and the homogenization of skin dichromia. The state of the art of cosmetic brands placed on the market therefore indicates that this type of 2-in-1 product does not an ?ad hoc? dermatological performance has been obtained so far.

Not ? was a purpose sought? immunoprotective, rebalancing and normalizing the microbiome in which a real fusion is created between a non-occlusive and light, natural skin feel with properties? soothing and for the treatment of the various types of epidermis and the color coverage necessary to uniform ?the base of the face? to make the discolorations homogeneous. On these premises also not? been sought a naturalness? by 99%. Isn't human skin? only a sensorineural organ and a body temperature regulator but above all performs an important protective function of physical barrier by exercising various functions such as immune, metabolic and primary protection against infections. AND? the anatomical layer located above the dermis and subcutaneous tissue and ? a particular type of epithelial tissue, histologically defined as multilayered keratinized squamous epithelial tissue.

His state of health depends both on intrinsic, natural factors connected to the processes of general somatic aging and to the susceptibility to diseases, which affect the set of organs, tissues and the totality? of individuals (chronoaging), both from external or environmental factors involving the skin as an external covering organ, whose responsibility? principal ? attributable to the cumulative alterations produced by the sun's rays (photoaging).

Chronoaging determines in the skin, as in most of the tissues, alterations of the hypotrophic type, with loss of compactness and cellular undernourishment, which contrast with the alterations of photoaging of the hypertrophic type, with aspects of proliferative disorder. In the dermatological management of skin reactions involving itching, redness, skin rashes, folliculitis, hyperdryness and fissures, the protection and defense of the hydrolipidic mantle therefore plays a role of primary importance.

Patent publication GB2542873 (A) comprises a composition comprising at least one Pro-resolution pathway enhancer. Preferably the pro-resolution pathway enhancers are selected from omega-3 / omega-6 fatty acids, salicylic acid, resveratrol, resveratrol salicylate, perilla ocymoides seed oil, camellia japonica extract, poria coria extract, seed extract of Aleurites moluccana (Kukui), Camelina sativa seed oil, Dongbaek (Tsubaki) oil, Bifida ferment lysate and Lactobacillus ferment lysate.

Choi, Y.M. et al. have disclosed the hypolipidemic effect of lactobacillus ferment as a functional dietary supplement.

Summary of the invention

Object of the present invention ? a new generation dermatological composition of intermediate products between skin care and colored makeup base for the needs of those who do not like to weigh down their skin with opaque foundations, but instead want a ?hybrid? solution? that is placed in the middle? between skin care and make up.

The dermatological composition has finality? immunoprotective, rebalancing and normalizing the microbiome in which a real fusion is made between a non-occlusive and light, natural skin feel with properties? soothing and for the treatment of the various types of epidermis and the color coverage necessary to uniform ?the base of the face? to make the discolorations homogeneous.

The dermatological composition object of the present invention has the advantage of supporting the qualitative-quantitative composition of the normal commensal skin microflora, responsible for a delicate chemical-physical balance, offering an immediate moisturizing, soothing and re-epithelializing action as well as not damaging the optimal pH, keeping under control the loss of transepidermal water, the thinning of the lipid barrier and the altered composition of fatty acids

The dermatological composition object of the present invention allows the improvement of the epidermal imbalance and the covering of the discolorations of the skin.

Therefore the problem addressed by the present invention ? the provision of a dermatological composition that allows simultaneously to effectively increase the degree of hydration of the skin, the degree of elasticity? of the skin, to rebalance the skin microbiome and to uniform skin discolorations.

Another item? the procedure for the preparation of the dermatological composition with which the components and ingredients have been processed and stabilized.

Another item? the use of the composition for rebalancing the skin, increasing its degree of hydration and elasticity.

The dermatological composition, the process for its preparation and use will be described as defined in the attached claims, the definitions of which form an integral part of the present description.

Further characteristics and advantages of the dermatological composition, of the preparation process and of the use will result from the description of the embodiments of the invention, given as an indication of the invention.

Detailed description of the invention

The present invention refers to a dermatological composition based on curative topical compositions having a purpose? rebalancing of the skin microbiome or that allows the treatment of skin imbalances including dermatitis, eczema, itching, redness, psoriasis, atopic dermatitis, vitiligo and skin diseases caused by microbial and fungal agents.

AND? object of the present invention dermatological composition which acts as a rebalancing and modulator of the microbiome, improving the skin's immune defenses and, at the same time, increasing the degree of hydration and elasticity? of the skin and which reduces skin discolouration. Furthermore, the present composition also has an immunoprotective action. AND? it has in fact been found that a dermatological composition comprising:

0.1% to 1% (w/w) mixture of the following bacterial lysates:

- Lactobacillus acidophilus ferment lysate,

- Lactobacillus casei ferment lysate,

- Lactobacillus plantarum ferment lysate,

- Streptococcus thermophilus lysate,

from 0.1% to 11% (w/w) Titanium Dioxide,

0.1% to 2% (w/w) hydrogenated lecithin,

from 0.1% to 2% (w/w) of Vitamin C with a titre of about 50% in phytocomplex extracted from Rosa canina,

0.1% to 1% (w/w) hyaluronic acid sodium salt,

0.05% to 0.5% (w/w) blend of Althaea Officinalis leaf/root extract and Malva Sylvestris extract.

allows to simultaneously achieve the aforementioned advantages.

All the percentage values reported in this text refer to weight by weight percentages (abbreviated p/p) and refer to the total weight of the entire dermatological composition. In fact, the dermatological composition comprising a mixture of four probiotics consisting of Lactobacillus plantarum, Lactobacillus casei, Lactobacillus acidophilus and Streptococcus thermophilus, together with Titanium Dioxide, lecithin, Vitamin C in phytocomplex derived from Rosa canina, Hyaluronic acid sodium salt and a high high/medium molecular weight present in the mixture of natural mucilages extracted from Malva and Althea, allows for rebalancing of the skin microbiome, increasing the degree of hydration and elasticity? skin, and to reduce skin discolouration. The Lactobacillus or lactobacillus ? a genus of rod-shaped facultative anaerobic or microaerophilic Gram-positive bacteria. There are at least 60 species in nature and they make up most of the group of lactic acid bacteria, so called as almost all? of their members converts lactose and other sugars into lactic acid by lactic fermentation. Inactivated cultures of the bacterium Lactobacillus or of the bacterium Streptococcus thermophilus can be prepared by heat, according to the tyndallization method.

The Lactobacillus bacterium can originate from a variety of species, and ? an organism that is defined as a ?probiotic?.

The species object of the present invention are Lactobacillus acidophilus, Lactobacillus casei and Lactobacillus plantarum, which are those which confer the designation ?probiotic?.

More examples strains of Lactobacillus bacteria are referred to by their INCI names, e.g. Lactobacillus lysate, Lactobacillus ferment lysate, Lactobacillus filtrate, and so on. Street. In particular, Lactobacillus acidophilus ferment lysate, Lactobacillus casei ferment lysate and Lactobacillus plantarum ferment lysate.

The extracts of Lactobacillus are also exploitable, which are an extract obtained from the fermentation of the bacterium Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus plantarum, and the filtrate of the Lactobacillus ferment which is ? a filtrate of the product obtained from the fermentation of Lactobacillus.

Pi? preferably, ? the Lactobacillus ferment lysate which ? a product obtained from the fermentation of Lactobacillus.

Streptococcus or Streptococcus? a genus of gram-positive spherical-shaped bacteria, cocci, which usually grow in pairs or form chains. They are facultative anaerobic bacteria, with a preference for the anaerobic condition.

Mixtures containing inactivated cultures of the Streptococcus thermophilus bacterium or its ferments are also usable.

Streptococcus thermophilus can be in the form of ferments, lysed, or filtered either alone or in combination. AND? preferred the fermentation product of Streptococcus thermophilus. Streptococcus thermophilus can also be part of a blend with other probiotic ingredients, ferments, filtrates or lysates, and the like.

According to a preferred embodiment, ? preferred Streptococcus thermophilus lysate.

Preferably, the bacterial strains used in the present invention are derived from bacterial cultures of Lactobacillus plantarum HA-119, Lactobacillus acidophilus HA-122, Lactobacillus casei HA-108 and Streptococcus thermophilus HA-110, heat inactivated by the tyndallization method.

These probiotics interact with the person's skin microbiome and modulate the protective rebalancing response giving health benefits to the epidermis, allowing the prevention and treatment of skin imbalances including eczema, atopic dermatitis, acne, allergic inflammation or hypersensitivity to the skin. cutaneous. These probiotics can help modulate the skin microflora, the lipid barrier and the skin immune system, leading to the preservation of skin homeostasis and keeping the skin pH under control, the increase of which? really associated with different disreactivity? skin.

The skin microflora plays a significant role in the competitive exclusion of pathogens that are aggressive and cause not only infections in the skin but are involved in the processing of proteins, free fatty acids (FFA) and sebum. ? It is interesting to note how the resident microbiota can be considered "beneficial" for the normal and healthy host, but can become dangerous for the host in which the integrity of the skin is lacking, resulting in fissured, wounded, inflamed skin. Microorganisms can also play a role in atopic dermatitis(AD), eczema, rosacea, psoriasis and acne.Topical probiotic application of the dermatological composition of the invention is found to be useful for preventing or treating skin diseases associated with altered microflora.

Titanium dioxide? Is the mineral used in the present invention coated with lipophilic emulsifying substances to increase its dispersibility? and the dermoaffinity? cutaneous. These substances offer the possibility of stabilizing the composition object of the present invention.

The natural phytocomplex of Vitamin C used in the present invention derives from a dry freeze-dried aqueous extract of fruit titrated at 50% in vitamin C supported on maltodextrins, consisting of a particle size of 20 mesh to improve its solubilisation in an aqueous base and stabilized with acid ascorbic (vit. C exogenous) since? the natural source of Vit. C from fruit ? dependent on climatic conditions, rainfall, harvest time and soil organic constitution. His activity? antioxidant counteracts free radicals and regulates excess melanin production by epidermal keratinocytes, preventing and reducing skin spots.

The term hyaluronic acid, in the present invention, refers to a mucopolysaccharide formed by D-Glucuronic acid and N-Acetylglucosamine joined by a 1-3 glycosidic bond. The compound used? a sodium salt of hyaluronic acid whose molecular weight is between 1,000,000 and 1,800,000 daltons. Hyaluronic acid? a polymer traditionally used as eye lubricant in ophthalmology and joint lubricant in orthopedic surgery and which, from a dermatological point of view, is very well tolerated at concentrations up to 2%. Regulates the water content of the intracellular substance and the permeability of the connective tissue, acts as a cementing substance of the tissues to which it gives the typical plasticity, has properties anti-inflammatory and healing. It is present in the dermatological composition, of which it regulates the three-dimensional scaffolding, turgidity and hydration. Its presence involves tissue hydration by water retention, in fact it has the ability to? to increase its initial molecular weight by about 1000 times due to swelling in water, it also develops a barrier effect protecting the damaged skin on the surface (film forming capacity).

Marshmallow and Mallow have been used in the form of freeze-dried aqueous extracts from leaves and roots from cultivars of European origin, rich in natural polysaccharide mucilages (mucopolysaccharides), mainly represented by arabinogalactans and galacturus -ramnans, arabians and heteropolysaccharide glucans with a molecular weight of about 30,000 daltons containing D-galactose, L-rhamnose, D-glucuronic and D-galacturonic acid in molar ratios 1.2:1.0:1.0:1.0; L-arabinans and D-glucans. The dominant component of the mucilaginous fraction ? (1?6)-?-D-glucan. These mucilages used for topical use, with the? Humidity? of the skin, they form a viscous colloidal solution indicated as calming, emollient, soothing, anti-inflammatory for protection against irritation.

AND? has been characterized the molecular weight of the phytocomplex Malva and Altea to correlate its capacity? moisturizing, protective and adhesive mucus in synergy with hyaluronic acid. The study reveals that more than 30% (w/w) of the phytotherapeutic mucilages contained have a molecular weight > 20,000 daltons, which confirms their ability? film-forming that adheres to the unbalanced epidermis and protects it from contact with irritating agents (barrier effect).

AND? in fact, it has been surprisingly found that the combination between the effect given by probiotics and the ability? Film-forming given by the synergy between hyaluronic acid and a mixture of Althaea Officinalis leaf/root extract and Malva Sylvestris extract, it allows to achieve the rebalancing effect, the moisturizing effect, the elasticising effect of the present invention. The blend of Althaea Officinalis leaf/root extract and Malva Sylvestris extract? therefore an essential ingredient of the present dermatological composition.

According to a preferred embodiment, the dermatological composition comprises: from 0.3% to 0.7% (w/w) of a mixture of the following bacterial lysates:

- Lactobacillus acidophilus ferment lysate,

- Lactobacillus casei ferment lysate,

- Lactobacillus plantarum ferment lysate,

- Streptococcus thermophilus lysate,

According to a preferred embodiment, the dermatological composition can include one or more of the following additional components:

50% to 75% (w/w) water,

5% to 10% (w/w) coco-caprylate,

1% to 5% (w/w) C15-19 alkanes,

from 1% to 5% (w/w) of Shea Butter ethyl esters,

1% to 5% (w/w) dicapryl ether,

1% to 5% (w/w) polyglyceryl-6-polyhydroxystearate,

1% to 5% magnesium stearate,

1% to 5% (w/w) iron oxide (yellow dye),

1% to 5% (w/w) polyglyceryl-6-polyricinoleate,

0.1% to 1% (w/w) magnesium sulphate,

0.1% to 1% (w/w) sodium chloride,

0.1% to 1% (w/w) phenoxyethanol,

0.1% to 1% (w/w) silica,

0.1% to 1% (w/w) iron trioxide (red dye),

from 0.1% to 1% (w/w) of perfume,

0.1% to 1% (w/w) iron tetroxide (black dye),

0.1% to 1% (w/w) ethylhexylglycerin,

from 0% to 0.1% maltodextrin,

0% to 0.1% polyglyceryl-2-caprate,

0% to 0.1% (w/w) glycerin,

0% to 0.1% (w/w) alumina,

0% to 0.1% (w/w) Simmondsia Chinensis Seed Oil,

0% to 0.1% (w/w) stearic acid,

0% to 0.1% (w/w) sucrose stearate,

0% to 0.1% (w/w) ascorbic acid,

0% to 0.1% (w/w) glyceryl caprylate,

0% to 0.1% (w/w) Squalane.

According to a preferred embodiment, the dermatological composition comprises all the ingredients listed above.

According to a preferred embodiment, the dermatological composition can further include one of the following additional components:

- from 0.5% to 4% (w/w) of a mixture of iron oxide (yellow dye), iron trioxide (red dye), iron tetroxide (black dye); or

- 0.5% to 2% (w/w) of capryloyl glycine or blueberry seed oil or undecylenoyl phenylalanine or ceramide NP or Phophyra Umbilicalis algae.

The above dermatological composition, in fact, has the advantage that, simply by adding one of the ingredients listed below, It is possible to obtain different compositions having specific uses and effects, in addition to the basic effects of hydrating, elasticising and rebalancing the skin given by the dermatological composition itself.

The dermatological composition, in addition to the above ingredients, can including one of the following additional components:

from 0.5% to 4% (w/w) of mixture of iron oxide (yellow dye), iron trioxide (red dye), iron tetroxide (black dye), to reduce discolored skin spots; or from 0.5% to 2% (w/w) of capryloyl glycine, for oily skin and/or acne-prone skin, or

0.5% to 2% (w/w) cranberry seed oil for eczematous and/or psoriasis skin, or 0.5% to 2% (w/w) undecylenoyl phenylalanine for the treatment of melasma, or from 0.5% to 2% (w/w) of ceramide NP to improve the barrier function of dry and/or oily skin, or

from 0.5% to 2% (w/w) of Phophyra Umbilicalis seaweed, to confer an antioxidant and/or photoprotective action.

According to a preferred embodiment, the dermatological composition comprises lysates which are derived from bacterial cultures of respectively:

- Lactobacillus acidophilus HA-122,

- Lactobacillus casei HA-108,

- Lactobacillus plantarum HA-119,

- Streptococcus thermophilus HA-110,

wherein said bacteria are inactivated by heat, by the tyndallization method.

According to a preferred embodiment, the dermatological composition comprises titanium dioxide microencapsulated in lecithin.

According to a preferred embodiment of the dermatological composition, the mixture of Althaea Officinalis leaf/root extract and Malva Sylvestris extract comprises a mucopolysaccharide of which more than one? of 30% (w/w) has a molecular weight greater than 20,000 Daltons.

According to a preferred embodiment of the dermatological composition, the Althaea Officinalis leaf/root extract and the Malva Sylvestris Officinalis extract are in a weight ratio of about 1:1.

Another object of the present invention ? that of obtaining a probiotic dermatological composition which includes emollients, lubricants, emulsifiers, thickeners, humectants which allows for a filming action for the hold and duration of color coverage on the face, without resorting to the presence of silicones, petrolatum, PEG and other occluding factors that worsen the effects deriving from the interaction with humidity? superficial skin, perspiration and related salinity, dust particles and smog from city life.

An additional advantage of the dermatological composition ? the definition of a dermatological composition which, based on the ingredients as described in claims 1 and 2, can generate a matrix of possible topical combinations to improve the curative and skin dyschromia reduction performance of new cosmetic products ?fusion? between skin care and makeup.

The preparations based on these compositions must be able to form a non-occlusive film-forming film on the unbalanced skin and be capable of exerting a protective barrier action against attacks from the external environment, for example dust, germs, small insects, which can worsen the skin. In fact, the insulted skin does not ? more able to fully play its role: the protective barrier, partially destroyed,? less efficient both internally and externally. From the inside there is a dispersion of body fluids rich in water, proteins and mineral salts, from the outside micro-fissures open which make the passage to impurities pervious. and bacteria from the surrounding environment, and what? create a difficult situation? because? becomes the main cause of infections.

On the basis of the type of aqueous continuous phase emulsion chosen, the bioadhesive characteristics? polymers, emollient oils, the antioxidant system, viscosifying excipients to obtain a thick cream or a fluid milk and the consequent conservation system selected to avoid microbial contamination, we must therefore focus on ingredients with a high tolerability profile. and low percutaneous absorption, to prevent the onset of allergic reactions which would imply important contraindications to a soothing and anti-reddening treatment.

Are the mucoadhesive biopolymers, viscosity stabilizers to be selected with particular attention? and emollients and skin conditioners, preferring those that have the advantage of offering the formation of protective films homogeneously dispersed on the skin for the protection and strengthening of the skin barrier, where dermatitis can generate acute phenomena of dehydration, flaking with signs of irritation, redness, itching, infections. The functionality? lenitiva also provides that the preparation has a highly moisturizing and emollient efficacy, particularly suitable for combating the typical dryness of sensitized and reactive skin. The prerogative of an optimal spreadability? and softness of the preparation, and immediate absorption, ? necessary condition for product compliance, which must not n? ?to brake? on the skin n? have an excessive need for excessive massaging, which would lead to a too prolonged mechanical insult, but flow, be quickly reabsorbed, hydrate and soothe to help give immediate relief in case of burning, cover discolored spots homogeneously and with perfect bioadhesion.

Table 2 shows the dermatological composition of the invention with the active dermatological variants and the rheological additives and basic excipients.

Table 2

Where, in Table 2, C77492 ? iron oxide (yellow dye), CI 77491 ? iron trioxide (red dye), CI77499 ? iron tetroxide (black dye).

The proposals are extremely diversified in the compositions since? articulated both by age target? of the consumer and for epidermal target and function as modulators of the physiological functions altered for various causes (chronoaging, diseases, photoexposure).

Another item? a process for the preparation of the cosmetic composition which allows to obtain a stable composition.

The preparation process consists of some pre-mixing phases which will be carried out with accuracy, controlling the temperatures and pressures of execution or the control of the vacuum in the production equipment.

The procedure for the preparation of the dermatological composition includes the following steps:

A) preparation of an aqueous solution or suspension comprising:

- Lactobacillus acidophilus ferment lysate,

- Lactobacillus casei ferment lysate,

- Lactobacillus plantarum ferment lysate,

- Streptococcus thermophilus lysate,

B) preparation of a mixture comprising:

- titanium dioxide,

- hydrogenated lecithin,

- vitamin C with a titre of about 50% in phytocomplex extracted from Rosa canina, - hyaluronic acid sodium salt,

C) preparation of an aqueous solution comprising a mixture of Althaea Officinalis leaf/root extract and Malva Sylvestris extract;

D) preparing an emulsion by adding the aqueous solution prepared in step C) to the mixture prepared in step B).

E) add the solution or suspension of step A) to the emulsion prepared in step D).

According to a preferred embodiment of the process, step A) and/or step B) ? also performed by sonication at about 20 KHz for a time between 3 and 15 minutes.

According to a preferred embodiment of the process, step C) and/or D) is carried out at a temperature of about 75°C.

According to a preferred embodiment of the process, step E) is carried out at a temperature of about 35°C.

The details of the preparation process will be described in detail below.

Step A): Preparation of the lactic ferment mix (probiotic phase).

The 4 lactic ferments (Lactobacillus plantarum, casei, acidophils and Streptococcus thermophilus), after careful weighing, are introduced one at a time into a UIP 200 HBT type mixer-tank for sonification in which it was already been introduced a quantity? weighing of purified water of pharmaceutical grade 1 equal to 10 times the total weight of the ferments.

After introducing the ferments, the container is mechanically closed and a residual pressure of about 0.4 atm is created by means of a vacuum pump (preferably the Edwards model).

Then begins the phase of slow stirring of the mixture through the rotating blades of the mixer, preferably at a speed? of 600 rpm for 4 minutes.

After this phase, the sonication process begins with a power of 20 kHz for 15 minutes. After this time, the sonication is interrupted while the stirring continues with the blades rotating at a speed of 100%. reduced to 400 rpm for a further 6 minutes.

Then follows the process of filtration of the mixture cos? obtained using the counterthrust of the vacuum tank hermetically connected to a closed filtering system consisting of two bell filters connected to each other, the first with a filtration degree of 2 microns and the second with 1 microns. All the dispersed mixture is passed through the two filters in such a way that the parts above 1 micron (which constitute the inert matrix of our lactic ferments) are retained.

The filtrate, always kept under vacuum, represents the biologically active and skin-compatible part of the composition, and is? made up of 90% water and 10% tyndallized probiotic lysate.

Step B): Production of the liposome containing titanium dioxide, hydrogenated lecithin and hyaluronic acid sodium salt (liposomal phase).

AND? the most phase complex of the entire process, since the subsequent possibility depends on the good result of the formation of the liposome to obtain a product with excellent spreadability, dermocompatible and well tolerated by the skin.

In a turboemulsifier - sonicator with double jacket for water recirculation, kept thermostated at 55?C, a quantity medium chain C8-C18 fatty acids (coco-Caprylate) between 5-10% and kept stirring at 50°C for 5 minutes. The container is then placed under vacuum with a depression equal to -0.6 atm.

Is then added the amount? dose of hydrogenated lecithin previously dispersed in coco-caprylate in a ratio of 1:3. Mixing is activated at 800 rpm for 10 min.

Are then prepared separately the exact quantities? of Hyaluronic acid sodium salt and Rosa canina extract titrated in Vitamin C and each dissolved separately in grade 1 purified pharmaceutical water and brought to a temperature of 50?C under slow stirring.

When the two solutions are visibly perfectly transparent (complete solution), keeping them always at 50°C, the sodium hyaluronate solution is drawn in sequence first and then the one with the rosehip extract while stirring continues at 800 rpm for 3 minutes.

The turbine is then activated for 4 minutes and brought to a speed? of 2800 rpm. At the end of this phase the turbine is switched off while the stirring continues at 800 rpm for a further 3 minutes. After this time the sonicator is activated for 3 minutes at 20 kHz power. The implant is then stopped, while a sample is taken and placed under microscopic observation at 4000 immersion magnifications to check the correct formation of our liposome containing titanium dioxide, sodium hyaluronate and Rosa Canina extract. We also proceed to a test of stendibilit? on the glass plate to check the perfect stability?, adhesiveness? and coverage of our liposome.

Step C): Preparation Hydrophilic phase.

The part of the hydrophilic ingredients of the dermatological composition, made up of dry extracts of Marshmallow and Mallow titrated in natural mucilages, is added to the total water to the mixture of the various hydrophilic components and kept under constant stirring at a temperature of 75°C.

Step D): Emulsification.

The liposomal phase (prepared in step B)) is combined with the other lipophilic components and the emulsifier to proceed with the preparation of the dermatological composition with the direct emulsion technique under vacuum.

The preparation turboemulsifier is filled with the hot total lipophilic phase (liposomal phase prepared in step B lipophilic ingredients). Upon reaching the temperature of 75°C, the total hydrophilic phase (prepared in step C (hydrophilic ingredients) is added to the lipophilic phase under stirring with a turbine at 3000 rpm for 20 minutes always at 75°C.

Step E): Cool down and final.

At the end of step D) slow cooling is carried out until the temperature of the composition is brought to a temperature of 35°C. At this point the probiotic phase (prepared in step A) is added, stirring at low speed. until completely homogenized.

The thermolabile components of the dermatological composition are then added, such as preservatives and essences.

The quantities? of the ingredients employed of the process are the same as those of the dermatological composition described above, including the preferred embodiments.

Another item? the dermatological composition obtainable from the above-described process, including the various preferred embodiments.

Another item? the use of the above-described dermatological composition, including the preferred embodiments, for skin rebalancing, for increasing the degree of hydration, and for increasing the degree of elasticity? of the skin.

All ingredients for the preparation of the dermatological composition are widely commercially available, including for the cosmetics industry.

EXPERIMENTAL PART EXAMPLE OF OBSERVATIONAL DERMATOLOGICAL STUDY relating to the anti-aging rebalancing foundation with probiotics, whose dermatological composition corresponds to that of the first column of Table 2 above.

Purpose of the study? the evaluation of the moisturizing, elasticising and unifying skin discoloration efficacy of a probiotic-based foundation for daily treatment. The study includes 1 week of treatment.

Inclusion criteria: the study ? was conducted on 10 healthy female subjects, of Caucasian ethnicity, of age? aged between 25 and 60, with a skin condition of dry, normal to dry, oily, normal to combination skin and mild/medium discolouration.

Non-inclusion criteria: all subjects who do not meet the inclusion criteria described above, pregnant or breastfeeding women, the presence of allergies and sensitivity? to cosmetic products for topical use, women on pharmacological therapy and a history of atopia. After the enlistment? the subjects' compliance with the inclusion/non-inclusion criteria and the baseline conditions (T0) of the skin parameters under study were evaluated.

For the evaluation of the moisturizing effect and the elasticising effect of the product? a skin area was selected on the antero-inner surface of the forearm of each volunteer. After an acclimatization period of 15 minutes, the foundation in question is applied in a quantity equal to 2 mg/cm<2>.

ENDPOINTS: 1 hour (T1h) and 8 hours (T8h) after application ? the skin hydration index was evaluated. The tool used? a MoistureMeterSC Compact. Each measurement ? the expression of the average value of 5 measurements in succession on the area in which ? foundation was applied.

For the evaluation of the elasticising effect (antiage) ? the Elastimeter instrument was used 8 hours later (T8h) from the control of baseline conditions at (T0). Each measurement ? the expression of the average value of 5 measurements in succession on the area in which ? foundation was applied.

In addition to the measurement tests of skin parameters, the observational study also collected the assessments administered to the subjects through a self-assessment questionnaire (see below).

Interpretation of results.

I study ? was designed to confirm the moisturizing effect and the elasticizing effect (antier?). The positive effect of the foundation on the measured parameter is confirmed if more? of 50% of the subjects recorded an improvement and if in the self-assessment questionnaire administered the product performance ? perceived by at least 60% of the test subjects.

RESULTS: The results obtained in the observational study are reported in the following tables:

Tab 3. Skin hydration index values

Tab 4. Values of the elasticity index? cutaneous

Tab.5 : Self-assessment test

TABLE 3. Skin hydration index values

Tab. 3 - Skin hydration

TABLE 4: Values of the elasticity index? cutaneous

Tab 4 Elasticity? cutaneous

TABLE 5: Self-Assessment Test

Tab.5

Interpretation of results.

I study ? was designed to confirm the moisturizing effect, the elasticising (anti-aging) and uniforming effect of skin discolouration of the dermatological composition of the present invention. The positive effect of the dermatological composition (foundation) on the measured parameter is confirmed if more? of 50% of the subjects recorded an improvement and if in the self-assessment questionnaire administered the performance of the product was perceived by at least 60% of the subjects participating in the test.

Based on the results obtained above? Was it possible to state how the dermatological composition determines an increase in the skin hydration index of 20% and in the elasticity index? skin equal to 14.9%.

Claims (12)

1. Dermatological composition including: 0.1% to 1% (w/w) mixture of the following bacterial lysates: - Lactobacillus acidophilus ferment lysate, - Lactobacillus casei ferment lysate, - Lactobacillus plantarum ferment lysate, - Streptococcus thermophilus lysate, from 0.1% to 11% (w/w) Titanium Dioxide, 0.1% to 2% (w/w) hydrogenated lecithin, from 0.1% to 2% (w/w) of Vitamin C with a titre of about 50% in phytocomplex extracted from Rosa canina, 0.1% to 1% (w/w) hyaluronic acid sodium salt, 0.05% to 0.5% (w/w) blend of Althaea Officinalis leaf/root extract and Malva Sylvestris extract. 2. Dermatological composition according to claim 1, comprising one or more? of the following additional components: 50% to 75% (w/w) water, 5% to 10% (w/w) coco-caprylate, 1% to 5% (w/w) C15-19 alkanes, from 1% to 5% (w/w) of Shea Butter ethyl esters, 1% to 5% (w/w) dicapryl ether, 1% to 5% (w/w) polyglyceryl-6-polyhydroxystearate, 1% to 5% magnesium stearate, 1% to 5% (w/w) iron oxide (yellow dye), 1% to 5% (w/w) polyglyceryl-6-polyricinoleate, 0.1% to 1% (w/w) magnesium sulfate, 0.1% to 1% (w/w) sodium chloride, 0.1% to 1% (w/w) phenoxyethanol, 0.1% to 1% silica, 0.1% to 1% (w/w) iron trioxide (red dye), from 0.1% to 1% (w/w) of perfume, 0.1% to 1% (w/w) iron tetroxide (black dye), 0.1% to 1% (w/w) ethylhexylglycerin, from 0% to 0.1% (w/w) of maltodextrin, 0% to 0.1% (w/w) of polyglyceryl-2-caprate, 0% to 0.1% (w/w) glycerin, 0% to 0.1% (w/w) alumina, 0% to 0.1% (w/w) Simmondsia Chinensis Seed Oil, 0% to 0.1% (w/w) stearic acid, 0% to 0.1% (w/w) sucrose stearate, 0% to 0.1% (w/w) ascorbic acid, 0% to 0.1% (w/w) glyceryl caprylate, 0% to 0.1% (w/w) Squalane. 3. Dermatological composition according to any one of claims 1 to 2, comprising one of the following further components: 0.5% to 4% (w/w) mixture of iron oxide (yellow dye), iron trioxide (red dye), iron tetroxide (black dye); or 0.5% to 2% (w/w) capryloyl glycine or cranberry seed oil or undecylenoyl phenylalanine or ceramide NP or Phophyra Umbilicalis algae. 4. Dermatological composition according to any one of claims 1 to 3, wherein the lysates are derived from bacterial cultures respectively of: - Lactobacillus acidophilus HA-122, - Lactobacillus casei HA-108, - Lactobacillus plantarum HA-119, - Streptococcus thermophilus HA-110, wherein said bacteria are inactivated by heat by the tyndallization method. 5. Dermatological composition according to any one of claims 1 to 4 wherein, the titanium dioxide is microencapsulated in lecithin. 6. Dermatological composition according to any one of claims 1 to 5 wherein, the mixture of leaf/root extract of Althaea Officinalis and extract of Malva Sylvestris comprises a mucopolysaccharide of which more? of 30% (w/w) has a molecular weight greater than 20,000 Daltons. 7. Dermatological composition according to any one of claims from 1 to 6 wherein, the leaf/root extract of Althaea Officinalis and the extract of Malva Sylvestris Officinalis are in a weight ratio of about 1:1. 8. Process for preparing the dermatological composition according to any one of claims 1 to 7 comprising the following steps: A) preparation of an aqueous solution or suspension comprising: - Lactobacillus acidophilus ferment lysate, - Lactobacillus casei ferment lysate, - Lactobacillus plantarum ferment lysate, - Streptococcus thermophilus lysate, B) preparation of a mixture comprising: - titanium dioxide, - hydrogenated lecithin, - vitamin C with a titre of about 50% in a phytocomplex extracted from Rosa canina, - hyaluronic acid sodium salt; C) preparation of an aqueous solution comprising a mixture of Althaea Officinalis leaf/root extract and Malva Sylvestris extract; D) preparing an emulsion by adding the aqueous solution prepared in step C) to the mixture prepared in step B); E) add the solution or suspension of step A) to the emulsion prepared in step D). 9. Process according to claim 6, wherein step A) and/or step B) ? also performed by sonication at about 20 KHz for a time between 3 and 15 minutes. 10. Process according to any one of claims 6 to 7, wherein step C) and/or D) is carried out at a temperature of about 75°C. 11. Dermatological composition obtainable from the process according to any one of claims 8 to 10. 12. Use of the dermatological composition according to any one of claims 1 to 7 or 11, for rebalancing the skin, for increasing the degree of hydration and for increasing the degree of elasticity of the skin. of the skin.